Drug Trial Radar · NCT05249101
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Aug 15, 2022
Primary completion
Jun 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- CG Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on a first line fluoropyrimidine-based chemotherapy (e.g., FOLFIRINOX). In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of ivaltinostat. In Phase 2, patients will be randomized in a 1:1 ratio to the combination of ivaltinostat and capecitabine or to capecitabine monotherapy. A fixed dose for capecitabine 1000 mg/m2 orally twice daily will be taken on Days 1 to 14, and the RP2D of ivaltinostat will be administered intravenously once a week for 2 weeks, followed by 1 week of rest. One cycle consists of 21 days. Tumor response during study treatment will be assessed every 6 weeks up to Cycle 10, then every 9 weeks afterwards using RECIST v1.1 criteria.
Conditions
- Metastatic Pancreatic Adenocarcinoma
Interventions
IvaltinostatDrug
Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
CapecitabineDrug
Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) in phase 1Time frame: 15 months
- Incidence of treatment emergent AEs in phase 1Time frame: 15 months
- Treatment emergent changes in clinical laboratory tests in phase 1Time frame: 15 months
- Progression-Free Survival (PFS) in Phase 2Time frame: 15 months
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
Hoag Medical Group
Newport Beach, California
UCSF Medical Center
San Francisco, California
UCLA Hematology/Oncology, Gastrointestinal Oncology
Santa Monica, California
University Cancer and Blood Center
Athens, Georgia
Community Health Network
Indianapolis, Indiana
Norton Cancer Institute Audubon
Louisville, Kentucky
University Medical Center New Orleans
New Orleans, Louisiana
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Clinical Research Alliance
Westbury, New York
Penn State Hershey Cancer Institute
Hershey, Pennsylvania
The University of Texas Southwestern Medical Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Virginia Cancer Specialists
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.